Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124189693 | 12418969 | 3 | F | 20160923 | 20160531 | 20160928 | EXP | PHEH2016US013285 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160928 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124189693 | 12418969 | 1 | SS | TAFINLAR | DABRAFENIB MESYLATE | 1 | Oral | 100 MG, QD (ONCE IN THE MORNING AND ONCE AT NIGHT) | 6ZP4889 | 0 | 100 | MG | QD | ||||||
| 124189693 | 12418969 | 2 | SS | TAFINLAR | DABRAFENIB MESYLATE | 1 | Oral | 200 MG, QD (TWO 50MG IN MORNING AND AND TWO AT NIGHT) | 0 | 200 | MG | QD | |||||||
| 124189693 | 12418969 | 3 | SS | TAFINLAR | DABRAFENIB MESYLATE | 1 | Oral | 300 MG, QD (TWO 75MG IN THE MORNING AND TWO IN EVENING) | 0 | 300 | MG | QD | |||||||
| 124189693 | 12418969 | 4 | SS | TAFINLAR | DABRAFENIB MESYLATE | 1 | Oral | 150 MG, QD (75MG IN THE MORNING AND 75MG AT NIGHT) 2 DF QD | 0 | 150 | MG | QD | |||||||
| 124189693 | 12418969 | 5 | SS | TAFINLAR | DABRAFENIB MESYLATE | 1 | Oral | (75 MG X 2) MG | 0 | 300 | MG | BID | |||||||
| 124189693 | 12418969 | 6 | PS | TASIGNA | NILOTINIB | 1 | Unknown | U | 22068 | ||||||||||
| 124189693 | 12418969 | 7 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Unknown | U | 0 | ||||||||||
| 124189693 | 12418969 | 8 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 124189693 | 12418969 | 9 | C | LISINOPRIL. | LISINOPRIL | 1 | Unknown | U | 0 | ||||||||||
| 124189693 | 12418969 | 10 | C | B6 | PYRIDOXINE HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 124189693 | 12418969 | 11 | C | POTASSIUM GLUCONATE | POTASSIUM GLUCONATE | 1 | Unknown | U | 0 | ||||||||||
| 124189693 | 12418969 | 12 | C | MAGNESIUM | MAGNESIUM | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124189693 | 12418969 | 1 | Product used for unknown indication |
| 124189693 | 12418969 | 6 | Product used for unknown indication |
| 124189693 | 12418969 | 7 | Product used for unknown indication |
| 124189693 | 12418969 | 8 | Product used for unknown indication |
| 124189693 | 12418969 | 9 | Product used for unknown indication |
| 124189693 | 12418969 | 10 | Product used for unknown indication |
| 124189693 | 12418969 | 11 | Product used for unknown indication |
| 124189693 | 12418969 | 12 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124189693 | 12418969 | Acne | |
| 124189693 | 12418969 | Alopecia | |
| 124189693 | 12418969 | Fatigue | |
| 124189693 | 12418969 | Headache | |
| 124189693 | 12418969 | Lethargy | |
| 124189693 | 12418969 | Malaise | |
| 124189693 | 12418969 | Quality of life decreased | |
| 124189693 | 12418969 | Rash | |
| 124189693 | 12418969 | Skin papilloma |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124189693 | 12418969 | 1 | 20160504 | 0 |